Sarraf Pasha

SEC Form 4 insider trading activity

Sarraf Pasha has filed 3 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Aug 28, 2026.

On the most recent filing, Sarraf Pasha is listed as Director at Cue Biopharma, Inc. Inside the rolling window, Sarraf Pasha reported 1 open-market purchase totaling $100K in CUE and no open-market sales.

Companies traded

Other insiders at CUE

Insider Buying

$100K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
CUE
Sarraf Pasha
Purchase$100KJan 2SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Sarraf Pasha made?

Sarraf Pasha has filed 3 SEC Form 4 filings (7 transaction rows) across 1 company since 2026.

Which companies does Sarraf Pasha trade?

Sarraf Pasha has filed SEC Form 4 disclosures for 1 company, including CUE.

When was Sarraf Pasha's most recent SEC Form 4 filing?

Sarraf Pasha's most recent SEC Form 4 filing on Tracefour is dated Aug 28, 2026.

What is Sarraf Pasha's total buy and sell value in the current window?

Inside the rolling retention window, Sarraf Pasha bought $100K and sold $0 based on SEC Form 4 filings.

What was Sarraf Pasha's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 323,857 CUE shares on 2025-12-30, worth $100K, per SEC Form 4 filings.